Prevalence of Nocturnal Hypoventilation in Obese Subjects Fiited With Continuous Positive Airway Pressure for Obstructive Sleep Apnea / Hypopnea Syndrome
CAPNOSOH
2 other identifiers
interventional
139
1 country
1
Brief Summary
CAPNOSOH study is a single-center study conducted at Toulouse University Hospital, aiming to estimate the prevalence of obese and apneic subjects maintaining nocturnal hypoventilation under continuous positive airway pressure (CPAP).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Sep 2025
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 25, 2025
CompletedStudy Start
First participant enrolled
September 1, 2025
CompletedFirst Posted
Study publicly available on registry
September 3, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
May 1, 2027
September 3, 2025
August 1, 2025
1.7 years
August 25, 2025
August 25, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Prevalence of nocturnal alveolar hypoventilation
Prevalence of nocturnal alveolar hypoventilation will be diagnosed by transcutaneous oxy-capnography. Nocturnal alveolar hypoventilation is defined with PTcCO2 \> 49 mmHg more than 10% of the time of capnographic recording.
1 month
Study Arms (1)
Obese Patients with Obstructive Sleep Apnea/Hypopnea
OTHERInterventions
Patients will be monitored using transcutaneous oxy-capnography to evaluate the prevalence of nocturnal alveolar hypoventilation in these population. Nocturnal alveolar hypoventilation is defined with PTcCO2 \> 49 mmHg more than 10% of the time of capnographic recording.
Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, and the "Patient-Reported Hypoventilation Questionnaire".
Arterial blood gas analysis will be performed only in patients presenting nocturnal hypoventilation.
Plethysmography will be performed only in patients presenting nocturnal hypoventilation. It will be used to measure lung volume and assess pulmonary function. This non-invasive procedure involves the patient breathing into a device that measures changes in pressure within a sealed chamber.
The intervention will be performed only in patients presenting nocturnal hypoventilation. Spirometry with a reversibility test will be performed to assess lung function and evaluate the response to bronchodilators. The procedure involves measuring forced expiratory volume and forced vital capacity before and after the administration of a bronchodilator.
Clinical exam will be performed only in patients presenting nocturnal hypoventilation. It will consists of standard interview/clinical examination: vital signs, cardiological, pulmonary, abdominal, neurological examination, search for clinical signs of nocturnal hypoventilation, search for signs of hypoxia/hypercapnia, pulmonary auscultation.
Eligibility Criteria
You may qualify if:
- Obese patients (Body Mass Index \> 30 kg/m2)
- Fitted by one of the following providers: ASTEN, Vitalaire, Orkyn, ISIS, RespiO2, BASTIDE for \> 3 months with compliance of more than 4 consecutive hours per night in average during 3 months
- "Good quality" criteria for continuous positive airway pressure (CPAP) treatment: compliance \> 4 consecutive hours per night, unintentional leaks \< limit defined by the manufacturer, residual AHI \< 10/h
- Aged 18 to 80
- Affiliated or beneficiaries of the social security system or equivalent
- Having given written informed consent
- Able to understand instructions and information given
You may not qualify if:
- Patient under legal protection measure
- Non-compliant patients
- Pregnant or breast-feeding women (assessed on questioning)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CHU de Toulouse Hôpital Larrey
Toulouse, Occitanie, 31059, France
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 25, 2025
First Posted
September 3, 2025
Study Start
September 1, 2025
Primary Completion (Estimated)
May 1, 2027
Study Completion (Estimated)
May 1, 2027
Last Updated
September 3, 2025
Record last verified: 2025-08